Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis
Clinical Obesity · 2026-08 · 16 (4)
DOI: 10.1111/cob.70092 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Obesity, online erschienen am 17.06.2026. Verfasst von Shaikha Jabor Alnaimi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Fertility, Obesity, Overweight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Overweight and obesity are global health concerns linked to impaired female fertility. Weight‐lowering drugs are an alternative for achieving weight loss; however, their effect on natural female fertility is unclear. A systematic review and meta‐analysis were conducted to summarise the literature on the effects of weight‐lowering drugs on ovulation, conception, pregnancy and live birth rates. Inclusion criteria comprised interventional and observational studies involving women with overweight or obesity receiving weight‐lowering drugs, compared with non‐users, lifestyle modifications or other medications. MEDLINE, Embase, CINAHL, CENTRAL and ClinicalTrials.gov were searched, yielding 2731 records. After screening, seven clinical trials were included ( n = 575), six of which were randomised. Sample sizes ranged from 40 to 120 women aged 25.9–29.7 years. Six trials evaluated orlistat, while one assessed semaglutide. In four trials, orlistat was associated with a higher ovulation rate than lifestyle modifications. A meta‐analysis of ovulation rates comparing orlistat and metformin showed no significant difference (RR = 0.78, 95% CI: 0.41–1.49; p = 0.45). Two studies reported pregnancy rates: one found a higher rate with orlistat compared to lifestyle modifications (23.3% vs. 6.7%, p = 0.044), and another showed that adding semaglutide to metformin increased the pregnancy rate compared to metformin alone (35% vs. 15%, p < 0.05). Future studies should address current limitations and evaluate the effects of newer weight‐lowering drugs on natural pregnancy and live birth rates in adequately powered studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.
- Pharmacy Department, Hamad bin Khalifa Medical City, Hamad Medical Corporation, Doha, Qatar.
- Department of Pharmacy Practice, College of Pharmacy, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia.
- Research Department of Pharmacology, School of Pharmacy, University College London, London, UK.
ORCID-Profile: Shaikha Jabor Alnaimi
Zitieren
APA
Alnaimi, S. J., Alsugeir, D. M., Wei, L., Harvey, K., & Brauer, R. (2026). Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis. Clinical Obesity, 16(4). https://doi.org/10.1111/cob.70092
Vancouver
Alnaimi SJ, Alsugeir DM, Wei L, Harvey K, Brauer R. Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis. Clinical Obesity. 2026;16(4). doi:10.1111/cob.70092
BibTeX
@article{Alnaimi2026,
author = {Alnaimi, Shaikha Jabor and Alsugeir, Dana Muwafag and Wei, Li and Harvey, Kirsten and Brauer, Ruth},
title = {Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis},
journal = {Clinical Obesity},
year = {2026},
volume = {16},
number = {4},
doi = {10.1111/cob.70092}
}
EUVIMED